The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role […]
Drug Modification Drug modification involves altering the chemical structure of the drug itself (such as functional groups, amino acids or nucleic acid skeletons) and coupling the drug with known partial […]
Background of Dopamine and Its Receptors In 1957, the Swedish scientist Arvid Carlsson first discovered dopamine and proposed that dopamine is not only a precursor of norepinephrine, it is also […]
Compared with biological drugs, small molecule drugs have greater advantages in R&D cost and process maturity, and they are still the main battlefield for drug research and development. According to […]
With the continuous development of molecular biology technology, the relationship between gene mutations and diseases has gained more and more in-depth understanding. Nucleic acids have attracted much attention because of […]
1. Chemistry Modification Chemical modification represents one of the most effective approaches to enhance oligonucleotide drug delivery. Modification of the nucleic acid backbone, the ribose sugar moiety and the nucleobase […]
We have introduced antibiotics before, and its invention makes bacterial infections no longer a fear. However, there is a more terrifying microorganism-virus. Viruses are highly dependent on other living organisms […]
The birth of penicillin in 1943 opened the golden age of antimicrobial therapy. However, after the 1980s, large pharmaceutical companies faced major scientific challenges in finding new antibiotics to solve […]
The blood-brain barrier (BBB) refers to the barrier between blood plasma and brain cells formed by brain capillary walls and glial cells, and the barrier between plasma and cerebrospinal fluid […]
Lung Cancer 1.Tilelizumab’s second-line or third-line treatment of non-small cell lung cancer Phase III RATIONALE 303 trial reached its primary clinical endpoint. On November 17, BeiGene announced the interim analysis […]